News

Y-mAbs Highlights CD38-SADA Advancements at AACR Annual Meeting

Y-mAbs Highlights CD38-SADA Advancements at AACR Annual Meeting

Y-mAbs Showcases Groundbreaking Research at Leading Cancer Conference

Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB), known for its innovative biopharmaceutical approaches, has made significant strides in cancer treatment through novel radioimmunotherapy. Recently, the company presented key findings on CD38-SADA, a bispecific fusion protein, at a premier cancer conference. This event marks a pivotal moment in the company's journey to advance cancer therapeutics.

Understanding CD38-SADA and Its Significance

The poster presentation, titled “Preclinical and translational pharmacokinetic (PK) modeling of the self-assembling and disassembling (SADA) bispecific fusion protein CD38-SADA for first-in-human pretargeted radioimmunotherapy,” offered an in-depth look at CD38-SADA's plasma levels in animal models. This innovative fusion protein is designed to selectively target CD38-expressing tumors, harnessing the body's own defenses in the fight against cancer.

Mechanisms of Action and Plasma Kinetics

Research findings indicated that the non-radiolabeled CD38-SADA tetramers demonstrated high binding affinity to tumors during the initial pre-targeting infusion. The study analyzed the PK models which tracked how CD38-SADA levels fluctuated in circulation, revealing a crucial insight: the estimated linear clearance of low molecular weight CD38-SADA monomers was significantly faster than that of the tetramers. This information is vital as it helps in understanding tumor-to-normal tissue absorption ratios for subsequent treatments.

Clinical Implications and Future Trials

Dr. Brian Santich, Vice President of Research at Y-mAbs, highlighted that the preclinical models used not only provided insight into the behavior of CD38-SADA in vivo but also guided the design of the Phase 1 Trial 1201 for patients with relapsed/refractory non-Hodgkin lymphoma (NHL). The initiation of this trial marks an exciting milestone, as it paves the way for potentially transformative therapies in cancer treatment.

Details of the Presentation at the Conference

This notable presentation took place alongside prestigious researchers at the 2025 American Association for Cancer Research (AACR) Annual Meeting. The session highlighted the importance of ongoing research and collaboration in the biopharmaceutical sector, where shared knowledge can spur innovation and accelerate treatment development.

Research Collaboration and Technology Development

The SADA technology itself stems from a collaboration with Memorial Sloan Kettering Cancer Center (MSK), where Dr. Nai-Kong Cheung developed the underlying principles of SADA for radioimmunotherapy specifically. This collaborative effort underscores the significance of partnerships in advancing medical technology and cancer treatments.

About Y-mAbs and Its Innovative Product Pipeline

Y-mAbs stands out in the biopharmaceutical landscape as a company dedicated to creating cutting-edge products for treating serious illnesses like cancer. Their product line includes investigational therapies, notably the anti-GD2 treatment DANYELZA, which has become a beacon of hope for patients suffering from high-risk neuroblastoma. This diverse pipeline clearly demonstrates Y-mAbs' commitment to enhancing the quality of cancer care.

Regulatory Advantages and Clinical Impact

With each advancement, Y-mAbs not only seeks to optimize therapeutic effectiveness but also aims to align with regulatory standards that ensure patient safety and the efficacy of their offerings. Their proactive stance in clinical trials helps ensure that they remain at the forefront of biopharmaceutical innovations while delivering on their commitment to increase survival rates for patients battling various types of cancer.

Frequently Asked Questions

What is CD38-SADA?

CD38-SADA is a bispecific fusion protein that targets CD38-expressing cancer cells while being paired with a radionuclide for targeted radiation therapy.

What is the significance of the AACR Annual Meeting?

The AACR Annual Meeting is a key event in the research community, providing a platform for sharing groundbreaking findings and fostering collaboration among cancer researchers.

What are the expected outcomes of the Phase 1 Trial 1201?

The trial aims to assess the safety and efficacy of CD38-SADA in patients with relapsed/refractory NHL, potentially leading to new treatment paradigms.

How does Y-mAbs approach cancer treatment?

Y-mAbs is dedicated to developing innovative therapies that leverage unique mechanisms of action, often involving advanced technologies like radioimmunotherapy.

What are the future plans for CD38-SADA?

Future plans include expanding clinical trials and gathering data to support potential regulatory submissions and wider therapeutic applications for CD38-SADA.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Tampa General's Food Bet Earns a 2026 Innovation Award

Updated Category News Views 64

Hospital meals have long been the punchline nobody bothered to fix, which is why Tampa General Hospital's latest recognition deserves a closer look. The not-for-profit academic health system was named the 2026 Inno Pick by the Tampa Bay Business Journal for its Food as Medicine initiative, its fifth straight year landing among the publication's Inno Award honorees. Awards...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 68

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 52

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 49

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
Clear Aligner Results Depend on Discipline, Not Hype

Updated Category News Views 115

A Clear Tray Is Not a Magic Wand Transparent orthodontic trays sell a wonderfully tidy idea: straighten teeth without the metal-and-wire routine, take them out to eat, and carry on. Fair enough. But the useful message from Dr. Theresa Trapp is the part nobody should glide past: clear aligners are a treatment plan, not a cosmetic shortcut bought with good intentions....

Continue Reading
TEN Holdings Raises $1.0 Million as Dilution Looms

Updated Category News Views 66

A Small Raise With a Loud Message Nothing says “we need room to breathe” quite like selling 1,492,500 new shares for $0.67 apiece. TEN Holdings closed a roughly $1.0 million gross equity offering on November 20, 2026, and investors in NASDAQ:XHLD ought to look at this for what it is: a modest cash infusion that comes with immediate dilution. The company gets capital;...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 125

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Page Library Grant Makes a Practical Case for Access

Updated Category News Views 56

A library card is not much use if a family cannot reach the help behind it. That plain reality sits at the center of AZ Blue Health Choice’s $10,000 contribution to the Page Public Library Family Resource Center, announced November 20, 2026. This is a modest dollar figure in the grand scheme of health care, but it is aimed at the kind of everyday gaps that can become...

Continue Reading
Franklin County Trees Raise Funds and Honor Veterans

Updated Category News Views 66

Holiday charity works best when it gives people something tangible to gather around, and Franklin County has found a pretty sturdy version of that formula. Its eighth annual Festival of Trees opens at 4 p.m. Saturday, November 21, at the Franklin County 11/30 Visitors Center in downtown Chambersburg, carrying the theme A Salute To Veterans. More than 80 decorated trees...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 103

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionizing Senior Living: The BrainFit Gym Experience

Updated Category News Views 330

Introducing the BrainFit Gym at The Bristal The Bristal Assisted Living is taking a bold step towards promoting cognitive wellness among seniors with their newly launched BrainFit Gym. Located at The Bristal at York Avenue, this unique facility stands out as a pioneering initiative aimed at enhancing the mental capacities of its residents. With this innovative approach,...

Continue Reading
Bullish (BLSH) Stock Surges After Thrilling IPO Success

Updated Category News Views 262

Bullish Stock Makes a Remarkable Entrance on the Market Recently, the cryptocurrency exchange Bullish (BLSH) took the public market by storm with its much-anticipated initial public offering (IPO). Its shares soared following trading debut, generating excitement among investors and analysts alike. Key Highlights of the IPO Supported by the renowned billionaire venture...

Continue Reading
Medius Honored as Top Microsoft Partner for Innovative Finance

Updated Category News Views 118

Medius Named 2024 Microsoft ISV Partner of the Year Medius, a leader in Accounts Payable (AP) Automation and Spend Management solutions, has reached an impressive milestone by being honored as the 2024 Microsoft ISV Partner of the Year. This esteemed award showcases Medius' dedication to innovation and excellence in improving finance operations through technology. The...

Continue Reading
Day One Biopharmaceuticals Set to Reveal Q1 2025 Financials

Updated Category News Views 309

Day One Biopharmaceuticals Plans Q1 2025 Financial Report Day One Biopharmaceuticals (NASDAQ: DAWN) is gearing up for a significant event. The biopharmaceutical company, known for its dedication to developing targeted therapies for serious illnesses, has announced a live conference call and webcast set for early May 2025. This event offers a chance for stakeholders to...

Continue Reading
Navigating the Future of Nonprofit Fundraising in 2025

Updated Category News Views 441

Nonprofit Fundraising Trends for 2025 As we approach the year 2025, nonprofits are setting their sights on innovative tactics that will not only enhance their fundraising efforts but also embrace the changing dynamics of donor engagement. Recent insights reveal that the landscape of nonprofit fundraising is evolving, making adaptability a core component of success in the...

Continue Reading